Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: type 1 diabetes

Study: Can Avacopan Replace Steroids in ANCA-Associated Vasculitis?

Ruth Jessen Hickman, MD  |  May 13, 2021

A phase 3 trial described in The New England Journal of Medicine (NEJM) highlights the potential of a C5a receptor inhibitor, avacopan, for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.1 Avacopan may potentially offer a steroid-sparing option for the treatment of this serious disease. Current Treatment of ANCA-Associated Vasculitis Morbidity and mortality from ANCA-associated vasculitis have…

Filed under:ConditionsDrug UpdatesResearch RheumVasculitis Tagged with:ANCA-Associated VasculitisavacopanGlucocorticoidsSteroids

Total Knee Replacement Cost-Effective, Even with Obesity & Comorbidities

Lisa Rapaport  |  March 29, 2021

(Reuters Health)—Total knee replacement surgery can be a cost-effective procedure for patients with severe obesity and osteoarthritis (OA), even when they also have comorbidities such as cardiovascular disease or type 2 diabetes, a new study suggests. Researchers did a cost-benefit analysis for two patient populations (over 65 years, and age 50 to 65) who had…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:comorbiditiescostsObesityOsteoarthritistotal knee replacement

Myositis & the Heart: New Perspectives on the Pathogenesis & Management of Cardiac Involvement in Myositis

Carina Stanton  |  February 18, 2021

Experts discuss the diagnosis and treatment of myositis-related cardiovascular disease.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2020cardiovascularheartHeart Diseasemyocarditismyositis

The Science of Empathy in Rheumatology

Leonard H. Calabrese, DO  |  January 19, 2021

Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…

Filed under:ConditionsPatient Perspective Tagged with:Empathy

Mitigating Preeclampsia Risk May Reduce Preterm Birth, Cesarean Delivery

Mary Beth Nierengarten  |  December 14, 2020

Interventions targeted at mitigating the risk of preeclampsia may reduce preterm birth and cesarean delivery in women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis. That’s one key finding of a retrospective study published in Arthritis Care & Research.1 The study set out to quantify the mediated effects of autoimmune conditions on adverse…

Filed under:ConditionsResearch Rheum Tagged with:preeclampsiapregnancy

Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020

Keri Losavio  |  November 19, 2020

In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – GoutGoutpegloticaseserum uric acid

Study: DPP4 Inhibitors Yield Promise for Systemic Sclerosis Treatment

Ruth Jessen Hickman, MD  |  November 12, 2020

A recent paper in Arthritis & Rheumatology opens up the possibility of a new research avenue to treat systemic sclerosis: dipeptidyl peptidase 4 (DPP4) inhibitors, a previously approved therapy for type 2 diabetes.1 Work in mouse models and on skin samples from systemic sclerosis patients suggests these drugs pose a promising area of future translational…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:DPP4 inhibitorsystemic sclerosis (SSc)

Studies Examine Peripheral Nervous System Disease in Lupus Patients

Linda Childers  |  November 12, 2020

Although systemic lupus erythematosus (SLE) affects both the central nervous system (CNS) and peripheral nervous system (PNS), past research has primarily focused on how lupus affects the CNS. Now, an international, inception cohort study, “Peripheral Nervous System Disease in Systemic Lupus Erythematosus,” published in Arthritis & Rheumatology, has examined different types of PNS disease to…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:central nervous systemperipheral nervous systemquality of life

New Findings on Hydroxychloroquine, Denosumab

Ruth Jessen Hickman, MD  |  November 12, 2020

ACR Convergence 2020—At two plenary sessions, speakers highlighted key findings, including results on the QTc interval in patients on hydroxychloroquine, and data from a study on denosumab vs. alendronate for glucocorticoid-induced osteoporosis. The QTc Interval & Hydroxychloroquine The safety profile and optimal dosing of hydroxychloroquine has been a topic for decades because it is known…

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:ACR Convergence 2020bone mineral density (BMD)COVID-19denosumabFracturesHydroxychloroquine (HCQ)Osteoporosis

High Opioid Prescription Rates Seen in Emergency Department-Treated Gout

Kurt Ullman  |  November 2, 2020

Acute gout can be very painful, causing patients to seek treatment in the emergency department. A retrospective study of pain interventions for gout in Rhode  Island found that nearly 30% of patients received prescriptions for opioid medications over 30 months. Of these prescriptions, over 80% were for patients who had never been exposed to opioids…

Filed under:AnalgesicsConditionsGout and Crystalline Arthritis Tagged with:Goutopioid crisis

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences